These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2545499)

  • 21. Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions.
    Reis H; Bertram S; Pott L; Canbay A; Gallinat A; Baba HA
    Pathol Oncol Res; 2017 Jan; 23(1):33-39. PubMed ID: 27276915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of MCP/CCR2 in patients of hepatocellular carcinoma and liver cirrhosis].
    Fang N; Fan X; Zhang XS
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):553-4. PubMed ID: 19912695
    [No Abstract]   [Full Text] [Related]  

  • 23. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expressions of MDM2 and MMP-7 in normal liver, cirrhosis, hepatocellular carcinoma tissues].
    Kang KF; Zhang X; Chen XW
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):67-8. PubMed ID: 20128976
    [No Abstract]   [Full Text] [Related]  

  • 25. Liver transplantation for hepatocellular carcinoma without preoperative tumor biopsy.
    Compagnon P; Grandadam S; Lorho R; Turlin B; Camus C; Jianrong Y; Lainé F; Meunier B; Deugnier Y; Boudjema K
    Transplantation; 2008 Oct; 86(8):1068-76. PubMed ID: 18946344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between rifamycin-SV (R-SV) related hyperbilirubinaemia and antipyrine clearance as a new test of liver function in cirrhosis.
    Persico M; Romano M; Villano N; Montella F; Gentile S
    Eur J Clin Invest; 1994 Mar; 24(3):201-4. PubMed ID: 8033955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Regulation of p53 and bcl-2 proteins to apoptosis and cell proliferation in liver cirrhosis and hepatocellular carcinoma].
    Feng D; Zheng H; Shen M; Cheng R; Yan Y
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):325-8. PubMed ID: 12080637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ether lipid tumour marker in human liver with hepatocellular carcinoma.
    Lin HJ; Wu PC; Ho JC
    Br J Cancer; 1980 Feb; 41(2):320-4. PubMed ID: 6245673
    [No Abstract]   [Full Text] [Related]  

  • 29. Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis.
    Jakate S; Yabes A; Giusto D; Naini B; Lassman C; Yeh MM; Ferrell LD
    Am J Surg Pathol; 2010 Jul; 34(7):935-41. PubMed ID: 20463569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signal Transducer and Activator of Transcription 3 for the Differentiation of Hepatocellular Carcinoma from Cirrhosis.
    Li YP; Wang WZ; Chen XQ; Li LB; Liang ZY; Ru K; Li JN
    Chin Med J (Engl); 2017 Nov; 130(22):2686-2690. PubMed ID: 29133756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
    Homeida M; Roberts CJ; Halliwell M; Read AE; Branch RA
    Gut; 1979 Jul; 20(7):596-601. PubMed ID: 488757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.
    Roberts CJ; Jackson L; Halliwell M; Branch RA
    Br J Clin Pharmacol; 1976 Oct; 3(5):907-13. PubMed ID: 973986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis.
    Kawasaki S; Imamura H; Bandai Y; Sanjo K; Idezuki Y
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1351-5. PubMed ID: 1551540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma.
    Rasi G; Serafino A; Bellis L; Lonardo MT; Andreola F; Zonfrillo M; Vennarecci G; Pierimarchi P; Sinibaldi Vallebona P; Ettorre GM; Santoro E; Puoti C
    World J Gastroenterol; 2007 Oct; 13(37):4986-95. PubMed ID: 17854142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant correlation between expression level of HSP gp96 and progression of hepatitis B virus induced diseases.
    Zhu XD; Li CL; Lang ZW; Gao GF; Tien P
    World J Gastroenterol; 2004 Apr; 10(8):1141-5. PubMed ID: 15069714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.
    Witjes CD; ten Kate FJ; Verhoef C; de Man RA; IJzermans JN
    J Clin Pathol; 2013 Aug; 66(8):687-91. PubMed ID: 23585667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating Lean Liver Volume as a Potential Scaler for
    Sinha J; Duffull SB; Green B; Al-Sallami HS
    Curr Drug Metab; 2020; 21(10):746-750. PubMed ID: 32410559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proliferating cell nuclear antigen (PCNA) activity in hepatocellular carcinoma, benign peri-neoplastic and normal liver.
    Mun KS; Cheah PL; Baharudin NB; Looi LM
    Malays J Pathol; 2006 Dec; 28(2):73-7. PubMed ID: 18376794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of breast cancer resistance protein in liver cirrhosis, hepatocellular carcinoma and peritumoral tissues].
    Wang YM; Huang GS; Hui YP; Zhang J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):227-9. PubMed ID: 19335991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.